H. Nina Kim, MD, MSc
Associate Professor of Science
University of Washington
- Review the clinical epidemiology–why chronic hepatitis B (HBV) is still a big deal in HIV care.
- Reflect on your own practice to ensure it incorporates the key components of clinical management of this coinfection, including treatment, staging and liver cancer screening.
- Discuss why HBV suppression is a critical goal in therapy.
- Explain the importance of HBV immunization.
Dr. Nina Kim is an Associate Professor of Medicine and Adjunct Associate Professor of Global Health at the University of Washington (UW). She is the Director of the Madison HIV/Hepatitis Coinfection Clinic at Harborview
This accredited continuing education activity is provided by American Academy of CME, Inc.
The 15th Annual American Conference for the Treatment of HIV (ACTHIV 2021) was held virtually May 20-22, 2021. The conference and this Best of ACTHIV web archive were supported by educational grants from Gilead Sciences; Janssen Therapeutics, Division of Janssen Products, LP; Merck & Co., Theratechnologies, and ViiV Healthcare.
H. Nina Kim, MD, MSc, Associate Professor of Medicine, University of Washington
Estimated time to complete: 30 minutes
This activity is intended for frontline providers of care to persons at risk for or who are living with HIV, including specialist and primary care Physicians, NPs, PAs, Nurses, and Pharmacists. Other HIV care team members are also encouraged to participate.
American Academy of CME is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
American Academy of CME, Inc. designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses Practitioners and Nurses:
American Academy of CME, Inc. designates this educational activity for 0.5 contact hours (0.4 pharmacotherapeutic contact hours).
American Academy of CME, Inc. has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until September 30, 2022. PAs should only claim credit commensurate with the extent of their participation.
All other members of the HIV Care team will receive a certificate of participation.
HOW TO RECEIVE CREDIT
There is no fee to participate in this activity. To obtain your certificate of credit/participation, you must read the CME/CE information, review the activity content, and complete the activity assessment and evaluation. Upon submission, your CE certificate will be emailed to you within 24 hours.
According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.
The opinions expressed in this accredited continuing education activity are those of the faculty, and do not represent those of the Academy, or ACTHIV. This educational activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.
Off-Label Usage Disclosure
This activity will discuss the use of adjuvanted HBV (HepB-CpG) in people with HIV.
H. Nina Kim, MD, MSc: has no relevant financial relationships with commercial interests to disclose.
The following individuals have no relevant financial relationships with ineligible companies to disclose: Beatrice Aladin, John Brooks, MD, Jose Castillo-Mancilla, MD, Sherrillyn Crooks, PA-C, Carlos del Rio, MD, Courtney V Fletcher, PharmD, Donna Futterman, MD, Rajesh Gandhi, MD, Mary Glenshaw, PhD, MPH, OTR/L, John JD Juchniewicz, MCIS, CHCP, FACEHP, H. Nina Kim, MD, MSc, Natalie Kirkwood, RN, BSN, JD, Harry Lampiris, MD, Sharon Lee, MD, Vincent Lo Re, MD, MSCE, Amber McCracken, Lorenzo McFarland, DHA, MPH, MSW, PMP, Paul Miniter, MS, Edward Moylan, RP, Asa Radix, MD, PhD, MPH, Dianne Rausch PhD, Renslow Sherer, MD, Cheryl Smith, MD, Susan Weiss, FNP-BC, MSN, AAHIVS
The following individuals have relevant financial relationships with commercial interests to disclose:
Jillian Baron, MD, MPH: Employee (Spouse/Partner) – IQVIA
Roger Bedimo, MD, MS: Advisory Board - ViiV Healthcare, Merck, Theratechnologies
Michelle Cespedes, MD, MS: Advisory Board: Gilead Sciences, ViiV Healthcare; Grant/Research Support - Merck
Eric Daar, MD: Consultant, Gilead Sciences, Merck, Genentech; Grant/Research Support: Gilead Sciences, ViiV Healthcare, Merck
Margaret Hoffman-Terry MD, FACP, AAHIVS: Advisory Board - ViiV Healthcare; Consultant - Gilead Sciences, ViiV Healthcare; Grant/Research Support - ViiV Healthcare; Consultant - Gilead Sciences, ViiV Healthcare
Igho Ofotokun, MD, MSc: Advisory Board – ViiV Healthcare, Accordant Health Services, Takeda
Tonia Poteat PhD, MPH, PA-C: Grant Recipient/Research Support: Gilead Sciences, ViiV Healthcare
Jennifer Price, MD, PhD: Consultant - Theratechnologies; Shareholder (Spouse/partner) - AbbVie, Bristol Myers Squibb, Johnson & Johnson, Merck;.Grant Recipient/Research Support - Gilead Sciences, Merck
Jason Schafer, PharmD, MPH: Advisory Board - Merck, ViiV Healthcare;.Grant Recipient/Research Support - Gilead Sciences, Merck
William Short, MD, MPH, FIDSA: Advisory Board - ViiV Healthcare; Consultant - ViiV Healthcare
Babaafemi Taiwo, MBBS: Advisory Board - Gilead Sciences, Merck, ViiV Healthcare;.Consultant - Gilead Sciences, Merck, ViiV Healthcare
Pablo Tebas, MD: Consultant: Merck, ViiV Healthcare
Melanie Thompson, MD: Grant Recipient/Research Support - Cepheid Inc, Cytodyn Inc, Frontier Biotechnologies, Gilead Sciences, GlaxoSmithKline, Merck Sharp Dohme, ViiV Healthcare
Andrea Weddle, MSW: Advisory Board: Merck
For questions related to CME/CE credit, contact CEservices@academycme.org
Hardware/Software Requirements To access this activity hardware and software requirements are noted below.
Windows Requirements: • Operating system: Windows XP Service Pack 2 or later • Browser: Internet Explorer 7 or later, Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connection • Flash: Adobe Flash Player 9 or later
Macintosh Requirements: • Operating system: Mac OS X v10.3 or later • Browser: Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connection • Flash: Adobe Flash Player 9 or later
Copyright 2021 American Academy of CME, Inc.
- Terrault NA, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560 - 99. Available at: https://pubmed.ncbi.nlm.nih.gov/29405329/
- HBV Primary Care Guidance (Feb 2020): https://www.hepatitisb.uw.edu
- Kim HN et al, Risk of HCC With Hepatitis B Viremia Among HIV/HBV - Coinfected Persons in North America. Hepatology. 2021 Mar; doi/10.1002/hep.31839. Available at: https://pubmed.ncbi.nlm.nih.gov/33780007/